Hims & Hers Health: Still Firing On Strong Cylinders

Update - May 21 

Hims has slumped some after the initial 30% rally on Monday. The telehealth company should benefit from offering a compound GLP-1 version at a discounted price. The big question is the financial impact. The stock only trades at 3x '24 sales targets making Hims intriguing on any further dip. 

-Hims & Hers Health (NYSE:HIMS) is offering customers access to compounded versions of Novo Nordisk's (NVO) semaglutide -- the active drug in its weight loss medication Wegovy -- at a fraction of the cost of the brand-name version.

-The company said plans for injections of its compounded semaglutide -- which is also sold as the type 2 diabetes med Ozempic -- start at $199 a month. It is also offering a $79 a month plan for an oral version of semaglutide. That is also known as Novo's diabetes pill Rybelsus.

Original article posted on May 7

• Hims & Hers Health, Inc. is leading in personalized health and building a strong health and wellness platform, leading to strong subscription growth.
• The company reported profitable growth in Q1 '24, with positive cash flows from adjusted profits.
• The stock is very cheap, trading at only 2x sales despite growing sales at a 40% clip.
• Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our subscriber-only portfolios. Learn More »

As long as the CEO can avoid self-inflicted wounds going forward, Hims & Hers Health, Inc. (NYSE:HIMS) appears headed back to the prior highs. The company is leading in personalized health and building a strong health and wellness platform to reward shareholders over the long term. My investment thesis remains ultra-Bullish on the stock following the recent multi-month dip, despite the company still delivering sizzling quarterly results.

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details.